-- 瑞銀證券週四發布的報告指出，梯瓦製藥（Teva Pharmaceutical Industries，簡稱TEVA）股價預計將進一步上漲，其估值有望重估，這主要得益於「不斷擴大的品牌成長」以及第一季業績公佈後強勁的產品線。 瑞銀表示，隨著產品線的不斷拓展（包括對Emalex Biosciences的收購），以及投資者對風險較低的生物製藥公司日益增長的“興趣”，市場對梯瓦的成長前景信心增強。同時，梯瓦正逐漸成為兼具“合理估值”和品牌成長潛力的罕見公司，此前該公司已表示地緣政治因素不會對其運營造成“重大影響”，這進一步緩解了市場對其的擔憂。 瑞銀還強調了梯瓦“對股東友好的資本配置”，指出該公司已加快業務發展戰略，並正在考慮提前進行股票回購，而不是“先前預期”。 報告稱，梯瓦管理層已表示對其他交易持開放態度，併計劃到2027年將淨債務與EBITDA的比率降至2倍以下，並在2026年達到投資級信用評級。 瑞銀維持對梯瓦製藥的買入評級，並將目標價從 36 美元上調至 42 美元。
Price: $35.15, Change: $-0.23, Percent Change: -0.65%
Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.
Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%
Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%